Literature DB >> 8789616

Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles.

N Pomara1, K Nolan, G Halpern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8789616     DOI： 10.1007/bf00970602

Source DB:  PubMed          Journal:  Neurochem Res        ISSN： 0364-3190            Impact factor:   3.996


× No keyword cloud information.
  11 in total

1.  A promising animal model of Alzheimer's disease.

Authors:  R E Tanzi
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

2.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

3.  Protection against Alzheimer's disease with apoE epsilon 2.

Authors:  C Talbot; C Lendon; N Craddock; S Shears; J C Morris; A Goate
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

4.  Hypersensitivity to scopolamine in the elderly.

Authors:  C Flicker; S H Ferris; M Serby
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

Authors:  R C Petersen; G E Smith; R J Ivnik; E G Tangalos; D J Schaid; S N Thibodeau; E Kokmen; S C Waring; L T Kurland
Journal:  JAMA       Date:  1995-04-26       Impact factor: 56.272

6.  Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model.

Authors:  S E Molchan; R A Martinez; J L Hill; H J Weingartner; K Thompson; B Vitiello; T Sunderland
Journal:  Brain Res Brain Res Rev       Date:  1992 Sep-Dec

7.  Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome).

Authors:  B T Hyman; H L West; G W Rebeck; S V Buldyrev; R N Mantegna; M Ukleja; S Havlin; H E Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.

Authors:  T Sunderland; P N Tariot; R M Cohen; H Weingartner; E A Mueller; D L Murphy
Journal:  Arch Gen Psychiatry       Date:  1987-05

10.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele.

Authors:  H Soininen; O Kosunen; S Helisalmi; A Mannermaa; L Paljärvi; S Talasniemi; M Ryynänen; P Riekkinen
Journal:  Neurosci Lett       Date:  1995-03-03       Impact factor: 3.046
View more
  2 in total

1.  Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults.

Authors:  Stefan J Teipel; Davide Bruno; Michel J Grothe; Jay Nierenberg; Nunzio Pomara
Journal:  Alzheimers Dement (Amst)       Date:  2015-05-07

2.  Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors.

Authors:  Stefan J Teipel; Enrica Cavedo; Harald Hampel; Michel J Grothe
Journal:  Front Neurol       Date:  2018-08-14       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.